SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED

Shandong Xinhua Pharmaceutical Company Limited

719 CNE100000411

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:05 31/05/2024 BST			5-day change	1st Jan Change
5.58 ^HKD	+0.36%		-.--%	-3.46%

05-29	Xinhua Pharmaceutical’s Sodium Bicarbonate Injection Passes Generic Drug Evaluation in China	MT
05-22	Xinhua Pharmaceutical's Depression Drug Gets Registration Approval in China	MT

Shandong Xinhua Pharmaceutical Co. Ltd. Provides Earnings Guidance for the First Quarter Ended March 1, 2013

April 12, 2013 at 10:38 am

Shandong Xinhua Pharmaceutical Co. Ltd. provided earnings guidance for the first quarter ended March 1, 2013. Based on the preliminary estimates, the company expects to record net loss attributable to share holders of RMB 8,000,000 or RMB 0.02 basic loss per share.

Latest news about Shandong Xinhua Pharmaceutical Company Limited

Xinhua Pharmaceutical’s Sodium Bicarbonate Injection Passes Generic Drug Evaluation in China	05-29	MT
Xinhua Pharmaceutical's Depression Drug Gets Registration Approval in China	05-22	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of Escitalopram Oxalate Tablets	05-22	CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation	04-11	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application	04-08	CI
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit	03-29	MT
Shandong Xinhua Pharmaceutical Proposes New Auditor	03-29	MT
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023	03-28	CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Xinhua Pharma's Ibuprofen Gets Registration Approval in China	03-13	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient	02-28	CI
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate	01-19	CI
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes	12-25	CI
Shandong Xinhua Pharmaceutical Gets Certificate for Registration of Levamlodiping Besylate Tablets	12-13	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)	12-13	CI
Respiratory Drug by Xinhua Pharmaceutical Unit Passes Regulatory Evaluation for Generic Drugs in China	12-04	MT
Xinhua Pharmaceutical's Nine-Month Profit Jumps 34%	30/10/23	MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Shandong Xinhua Pharmaceutical’s AntiCoagulant Tablets Get Drug Registration Certificate	18/10/23	MT
China Grants Marketing Approval for Shandong Xinhua Pharmaceutical's Uric Acid Medication; Shares Rise 4%	11/10/23	MT
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat	10/10/23	CI
Xinhua Pharmaceutical Unit's Clarithromycin Granules Passes Regulatory Evaluation	20/09/23	MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration	11/08/23	CI

Chart Shandong Xinhua Pharmaceutical Company Limited

Duration

Period

Chart Shandong Xinhua Pharmaceutical Company Limited

More charts

Company Profile

SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Companyâs main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.

Sector

Pharmaceuticals

Calendar

26/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED	-3.46%	1.19B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B